Trichosic

Trichosic™: Treatment for Sickle Cell Anemia

Trichosic™ is EGT’s product in development for the treatment of sickle cell anemia. Sickle cell anemia is a potentially lethal, inherited blood disorder in which the hemoglobin (oxygen carrying molecule) of red blood cell is defective. The abnormal hemoglobin found in sickle cell anemic patients causes the shape of the normally disc-shaped red blood cells to elongate and become sickle-shaped. As a result, they function abnormally and cause blockage of blood flow and small blood clots. These clots cause recurrent painful episodes called “sickle cell pain crises” and eventually damage many of the body’s critical organs.

To date, there is no cure for sickle cell anemia. Treatment of the symptoms and complications consists of a combination of fluids, painkillers, antibiotics and transfusions. Hydoxyurea, an anti-tumor drug, is also used as a treatment but is limited because of the extensive side-effects. Hydroxyurea acts to affect the induction of fetal hemoglobin in sickle cell treated patients. As a result, the fetal hemoglobin replaces a portion of the abnormal sickle red blood cell and reduces the symptoms.

Trichosic™ is the brand name of EGT’s active pharmaceutical ingredient, Trichostatin A. Trichosic™ is obtained through a chemical synthesis that has been found to induce fetal hemoglobin expression in the laboratory. Trichosic™ is in early stage pre-clinical development and will require additional efforts prior to initiating human clinical trials.

More information on Trichosic™ – click here